welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Hope in Translation: Bringing Gene Therapy to the Clinic
In 1987, scientists first uncovered the gene that is the target of mutations that causes Duchenne muscular dystrophy (DMD), a lethal muscle-wasting disease that affects about one in every 5,000 newborn boys. While the discovery of the dystrophin gene sparked hope that scientists could someday replace the mutated gene with a healthy one, turning this concept into a safe and effective treatment has been a decades-long challenge.
In drug discovery, the process of converting early biological insights into a therapy that can be tested in the clinic is known as translational research. It’s rigorous and very often painstaking work that happens behind the scenes, but the nonetheless is a critical bridge to bringing life-transforming treatments to patients. And in the journey of developing a gene therapy for DMD, scientists have had to overcome significant hurdles due to the complexity of the disease and the various challenges of engineering vector delivery systems.
rareRelated
-
Crispr Halted Muscular Dystrophy In Dogs. Someday, It Might Cure Humans.Today, our partner Dr. Eric Olson and hi...
-
How AAV Gene Transfer Works – General Audiencehttps://youtu.be/SUOskEqLpyY...
-
New CRISPR Method Takes on Duchenne Muscular DystrophyThe advance of CRISPR gene editing techn...
-
Dr. Eric Olson CRISPR/Cas9 Presentation at CureDuchenne Careshttps://www.youtube.com/watch?v=P-Q8HFXk...
-
New therapeutic approaches: I.9 Treatment of Duchenne muscular dystrophy: current efforts, bottlenecks and future pr...In the last decade a number of therapeut...
-
UT researcher, with CureDuchenne support, launches company to treat DMD using CRISPR/Cas9 technologyEric Olson, a molecular biologist, has s...
-
Nearly Half of Duchenne Muscular Dystrophy Patients Are Candidates for Gene TherapiesMore than 40 percent of boys with Duchen...